Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Radiation enteropathy Stories

2013-01-04 08:22:23

PRINCETON, N.J., Jan. 4, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or oral BDP) for the mitigation of morbidity and mortality associated with the gastrointestinal acute radiation syndrome (GI-ARS). Soligenix...

2012-10-01 02:30:35

PRINCETON, N.J., Oct. 1, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that results of a study in a canine model of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate) will be presented at a poster session entitled, "Post-exposure oral 17,21-beclomethasone dipropionate (BDP) improves survival in a canine gastrointestinal acute radiation syndrome (GI ARS) model." The presentation will be made...